COVID-19 Pfizer Information
Follow Us on Twitter
ADD TO CALENDAR: Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for
treating IMD in haematology patients
ADD TO CALENDAR: Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for
treating IMD in haematology patients
ADD TO CALENDAR: Looking deep into complexities of Multiple Myeloma (MM): how to decide the treatment and measure the outcomes?
Cresemba SmPC Link - Czech
Cresemba SmPC Link - English
Daurismo SmPC Link
Dosing Guide
Therapy Management Guide
Mylotarg SmPC Link
Salvage Leave Piece - Video Animation
MRD publication summary
Post HSCT Survival Leaflet
Blast Count Leaflet
Besponsa SmPC Link
BYOND Leaflet
ELN Guidelines for CML
Bosulif SmPC Link
Abstract Plain Language Summaries
This is Living with Cancer
What to Expect With Your Cancer Care During COVID-19 – Spanish Version
What to Expect With Your Cancer Care During COVID-19
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
Connect with Talent Acquisition
Investigator Information and How to Contact Us
Global Medical Grants Oncology Brochure
MagnetisMM-9 Clinical Trial
MagnetisMM-5 Clinical Trial
Some Older People Living with Cancer Aim for Remission but Lack Needed Resources to Help Make Treatment Decisions
Age: Addressing a Blind Spot in Cancer Care
African American Men’s Health Checklist
Digitally Empowered (a collaboration between Patient Empowerment Network and Pfizer)
Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for treating IMD in haematology patients
Looking deep into complexities of Multiple Myeloma (MM): how to decide the treatment and measure the outcomes?
Pfizer Medical Information
Discover the Oncology Development Program and Clinical Trials
MOA Panel
"Be A BsAb in MM" Photo Activity
advancinghemonccare.com
Hematologic Malignancies
COVID-19 Pfizer Information
Blood Cancer Community Video
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
Perspectives by Colleagues Video
Expert Video Dr. Vendetti on MRD
Expert Video Dr. Marks on prognostic significance of BMB
Watch Dr. Gordon Cook share details about BCMA and its potential as an immunotherapeutic target in MM
Watch Dr. Nina Shah explain developments in BCMA-directed therapies
Chapter 3: BsAbs as a potential therapeutic approach in MM
Chapter 2: BCMA is a therapeutic target in MM
Chapter 1: Immunosuppression in MM
Thanks for finding us at EBMT
Who We Are and What We Do
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.
Thanks for finding us at EBMT
Who We Are and What We Do
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.
Opportunities To Connect
Upcoming Opportunities
to Connect
Upcoming Opportunities to Connect
Symposium
A team member will respond to your inquiry.
Product Symposium
Learn About Our Oncology Approved Medicines
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
